Coefficient Bio: Everything to know about Anthropic's $400 million biotech acquisition

The move positions Anthropic in a $100B+ drug discovery market that's ripe for disruption, blending frontier models with wet-lab integration.

Anthropic is making strides in the AI space. The AI firm has acquired stealth startup Coefficient Bio for over $400 million in an all-stock deal. Closed in early April 2026, the acquisition pulls a tiny team of elite ex-Genentech researchers into Anthropic's Healthcare and Life Sciences group, pushing the AI lab's ambitions beyond smart chatbots into drug discovery.

Founded in late summer 2025 in New York City, Coefficient Bio has operated in near-total stealth for just 7-8 months before its explosive exit. Backed heavily by Dimension, which reportedly held about half the company, the startup assembled fewer than 10 experts focused on AI-native biotech tools.

Coefficient Bio: Tracing the origins

Coefficient Bio emerged from the computational biology powerhouse at Genentech's Prescient Design unit. Its co-founders include:

• CEO Aris Theologis, with prior stints at Evozyne and Paragon Biosciences in business development.

• CTO Nathan C. Frey, PhD, a former Group Leader and Principal Scientist who spearheaded AI for biomolecule design, lab-in-the-loop systems, and NVIDIA collaborations like BioNeMo.

• Samuel Stanton, a Principal ML Scientist.

The team blended machine learning engineers, scientists, and experimental biologists to tackle biology's toughest challenges. No public products or revenue surfaced, but their mandate was bold - build AI foundation models, generative tools, and autonomous systems for drug R&D - from molecule design and clinical planning to closed-loop experimentation integrating virtual simulations with physical labs.

This "artificial superintelligence for science" vision aimed to supercharge human flourishing by slashing discovery timelines in a field plagued by high failure rates and costs.

Anthropic's acquisition: What's bought now

The deal, valued at roughly $400 million, closed swiftly amid Anthropic's healthcare push. It follows the October 2025 launch of Claude for Life Sciences - a research accelerator that aligns with rival AI labs chasing domain-specific edges.

Sources describe it as an all-stock purchase, with Coefficient's full team -- nearly all Genentech alumni -- joining under leader Eric Kauderer-Abrams. No cash changed hands publicly, but the premium reflects scarcity in AI-biotech talent amid frothy 2026 M&A.

Strategic wins for Anthropic?

For Anthropic, this isn't a mere acquisition. Instead, it's a bet on transforming Claude from generalist to biotech competitor. Coefficient's tech slots into workflows for drug candidate ID, R&D strategy, and automated science, potentially yielding breakthroughs where traditional methods stutter.

Talent scarcity drives the price, too. Experts in biological foundation models are rare, enabling faster iteration on proprietary data loops that general AI lacks. It strengthens Anthropic against OpenAI and xAI in science, where success relies on AI genuinely accelerating discoveries, not just paper reviews.

The move positions Anthropic in a $100B+ drug discovery market that's ripe for disruption, blending frontier models with wet-lab integration.